Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2005

View Archived Issues

CMPD-167 protects macaques from vaginal SHIV transmission

Novel class of Factor XIIIa inhibitors synthesized by Apotex

Potential antiobesity therapeutics synthesized and tested by Schering-Plough

New indications for procarbazine hydrochloride in Japan

Alteon suspends enrollment in alagebrium trials

Homspera shows efficacy blocking development of airway hyperreactivity

First patient treated in phase I advanced AMD study of Litx

Hemospan completes phase II study

Neoprobe establishes corporate IND for Lymphoseek

Curacyte to merge with IBFB Pharma

Advitech and the CHULRC to test XP-828L for inflammatory bowel diseases

Amrad updates six-month progress

Avidex and Anodys complete collaboration in cancer vaccine development

Biogen Idec and Elan suspend Tysabri

Therapeutic benefits reported for teverelix in prostate cancer

Update on the antiretroviral activity of 873140

Pfizer reports new SSRIs for premature ejaculation and other disorders

Novel Streptomyces-derived antitumor agents discovered at Ecopia BioSciences

Coagulation factor VIIa inhibitors developed by Bristol-Myers Squibb

Abbott scientists impart novel vanilloid VR1 receptor inhibitors for pain therapy

Dual-action tachykinin receptor antagonists developed at AstraZeneca

Bristol-Myers Squibb scientists describe new CCR3 receptor antagonists

KSP inhibitors claimed by Chiron for the treatment of cancer

NeuroSearch researchers disclose new chloride channel blocking agents

Favorable pharmacokinetic and safety profiles reported for NNRTI BILR-355

HIV-1 develops resistance to AG-1859 but much slower than to lamivudine

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026